Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 4/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | PGR | P06401 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL6 | P05231 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | GLUL | P15104 | 1/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8168541 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL11206109 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL193712 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL18994229 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL5609666 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL93788 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL29450746 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL2510061 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL21973841 | 1.00 | G6PD (0.72) | G6PDSERPINA6HIF1ACYP3A4HSD17B10 | |
| SCHEMBL14983069 | 0.88 | G6PD (0.58) | G6PDSERPINA6CYP3A4CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-07-20 | — | — | US | disclosed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | disclosed |
| EP-4003362-A1 | ARTICLES COMPRISING STEROID DIMERS AND THEIR USE IN THE DELIVERY OF THERAPEUTIC AGENTS | Ripple Therapeutics Corporation (CA) | 2022-06-01 | — | — | EP | disclosed |
| EP-3996764-A1 | SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF | Ripple Therapeutics Corporation (CA) | 2022-05-18 | — | — | EP | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-11-11 | — | — | US | disclosed |
| US-20210113457-A1 | GLASS FORMULATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-04-22 | — | — | US | disclosed |
| US-10632075-B2 | Glass formulations and uses thereof | RIPPLE THERAPEUTICS CORPORATION (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190275167-A1 | GLASS FORMULATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275167-A1 | GLASS FORMULATIONS AND USES THEREOF | GBA2, AGER, GBA1 | G6PD 13/4885SERPINA6 1141/4885HIF1A 2789/4885 |
| US-20210113457-A1 | GLASS FORMULATIONS AND USES THEREOF | GBA2, AGER, GBA1 | G6PD 13/4885SERPINA6 1141/4885HIF1A 2789/4885 |
| US-10632075-B2 | Glass formulations and uses thereof | GBA2, AGER, GBA1 | G6PD 13/4885SERPINA6 1141/4885HIF1A 2789/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | G6PD 2109/4885SERPINA6 4/4885HIF1A 509/4885 |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | G6PD 2109/4885SERPINA6 4/4885HIF1A 509/4885 |
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | NR3C1, NR3C2, CYP21A2 | G6PD 86/4885SERPINA6 6/4885HIF1A 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.